• Skip to main content
  • Skip to primary navigation
  • Home
  • Community Schedule
  • Hospital Medicines (HML)
  • Application Tracker

Pharmac - Te Pātaka Whaioranga. Pharmac - Te Pātaka Whaioranga. Pharmac - Te Pātaka Whaioranga.

  • Te Rārangi Rongoā Pharmaceutical Schedule

    Pharmaceutical Schedule

    The Pharmaceutical Schedule lists all the medicines funded for New Zealanders.

    • Community Schedule

      Search for funded medicines

    • Hospital Medicines (HML)

      Search for funded medicines for hospitals

    • Schedule Updates

      The monthly update to the Schedule

    • Schedule resources

      Additional resources for community and hospital Schedules

    • About the Schedule

      An introduction to the Schedule

    • Rules of the Schedule

      For pharmacists and prescribers using the Schedule

    • Hospital Medical Devices

      Read about our work with contracting medical devices for hospitals

  • Te pūtea me ngā umanga rongoā Medicine funding and supply

    Medicine funding and supply

    Find out how PHARMAC decides what medicines to fund, how to apply for a medicine to be funded and other questions about medicines you might have.

    • Make an application

      Apply to have a medicine funded for everyone or an individual

    • Medicine notices (includes supply issues)

      Brand changes, supply issues and discontinuations

    • The funding process

      How funding applications are assessed

    • What you need to know about medicines

      Learn about generic medicines, biosimilars, vaccines and getting your prescription

    • Medicine supply management

      Order condoms and smoking cessation products. Learn about PHARMAC's role in medicine supply

  • Ngā pūrere hauora a te hōhipere Hospital medical devices

    Hospital medical devices

    PHARMAC contracts with device suppliers to ensure our hospitals can buy medical devices at fairer prices.

    • Category Information

      Find out which types of medical device we have contracted and the ones we're working on

    • Growing our role in medical devices

      The goal for our work in medical devices

    • Device Advice

      Read and subscribe to our devices newsletter

  • Treaty of Waitangi Te Tiriti o Waitangi

    Te Tiriti o Waitangi

    • Te Whaioranga

      PHARMAC's Māori Responsiveness Strategy

    • Hauora Arotahi

      The Māori health areas of focus

    • Programmes to support Māori health

      Scholarships, awards and programmes

    • How we work with Whānau Ora

      Working with communities and Māori health providers

  • Ngā karere me ngā rauemi News and resources

    News and resources

    Check the current consultations, RFPs and tenders. Find our key resources for prescribers, pharmacists, researchers and the public.

    • Consultations and decisions

      Consultations, RFPs, tenders and our decisions

    • News and updates

      Latest news from PHARMAC

    • Order publications

      How to order a printed publication

    • Seminars

      Watch previous seminars

    • COVID-19

      Our response to COVID-19

    • PHARMAC's research

      Articles and reports produced by PHARMAC

  • Mō About

    About

    Learn more about who PHARMAC is and our goals. There are details about our Board and our expert advisors.

    • Strategic Direction

      Our plan to deliver the best health outcomes for New Zealanders

    • Pacific Responsiveness Strategy

      Our strategy to support Pacific people to live healthy lives

    • Te Tiriti o Waitangi

      Our commitment to being Tiriti partners

    • What we do

      Learn more about PHARMAC's role and how we support the health system

    • Who we are

      Our Board, our senior leaders, and experts

    • How we get expert advice

      Advice we seek to make decisions

    • Working at PHARMAC

      Explore current vacancies

    • Contact us

      How to get in touch

Search

Search PHARMAC's corporate website

Search for funded medicines and Special Authority forms

Search for medicines funded in hospitals.

Check the progress of a medicine funding application

  1. Home
  2. About
  3. What we do
  4. Accountability information
  5. Official Information Act
  6. 2019 OIA responses

2019 OIA responses

Index of OIA responses sent in 2019

  • 16 December 2019: OIA response: Lamotrigine NPPA change

  • 11 December 2019: OIA response: MMR vaccine stock

  • 10 December 2019: OIA response: Antifungals data

  • 10 December 2018: OIA response: 2018-12-12 Research projects

  • 12 December 2019: OIA response: Adalimumab data

  • 9 December 2019: OIA response: Lamotrigine brand change

  • 5 December 2019: OIA response: Sildenafil

  • 4 December 2019: OIA response: Statins prices

  • 4 December 2019: OIA response: Lamotrigine NPPA data

  • 28 November 2019: OIA response: Lamotrigine contingency plan activation

  • 28 November 2019: OIA response: Male sex change hormones data

  • 27 November 2019: OIA response: Asthma inhalers data

  • 26 November 2019: OIA response: Fingolimod data

  • 25 November 2019: OIA response: Pembrolizumab and nivolumab

  • 25 November 2019: OIA response: Funded mental health drugs

  • 21 November 2019: OIA response: Cefuroxime data

  • 20 November 2019: OIA response: Pembrolizumab and nivolumab data, July to September 2019

  • 19 November 2019: OIA response: Meningitis vaccines communications

  • 14 November 2019: OIA response: Prescription numbers

  • 12 November 2019: OIA response on MMR vaccine

  • 31 October 2019: OIA Response: 2019-20 budget bid letter

  • 29 October 2019: OIA response: Venlafaxine and lamotrigine NPPA data

  • 24 October 2019: OIA response: Chloramphenicol data

  • 24 October 2019: OIA response: Anti-VEGF treatment

  • 24 October 2019: OIA response: Compassionate supply response

  • 16 October 2019: Asthma inhalers

  • 15 October 2019: OIA Response: Opioid substitution

  • 1 October 2019: OIA response: Lamotrigine safety

  • 26 September 2019: OIA response: Growth hormone data

  • 25 September 2019: OIA response: Venlafaxine brand use data

  • 18 September 2019: OIA response: Phenelzine supply

  • 17 September 2019: OIA response: Leuprorelin and goserelin data

  • 12 September 2019: OIA response: Psychometric testing

  • 1 August 2019: OIA response: Pembrolizumab and nivolumab data

  • 22 July 2019: OIA Response: Pfizer PHARMAC communications

  • 19 July 2019: OIA Response: Asthma and Respiratory Foundation payments

  • 16 July 2019: OIA Response: University of Auckland communications

  • 5 July 2019: OIA Response: Keith Petrie communications

  • 26 June 2019: OIA Response: Venlafaxine brand change data

  • 20 June 2019: OIA Response: Meningococcal vaccine meetings

  • 18 June 2019: OIA Response: Infliximab hospital purchase data

  • 18 June 2019: OIA Response: Adalimumab and etanercept data

  • 11 June 2019: OIA Response: MSTAC Minutes

  • 11 June 2019: OIA Response: Adalimumab, etanercept, infliximab and secukinumab data

  • 10 June 2019: OIA Response: Mesalazine data

  • 10 June 2019: OIA Response: Compounding data for antiepileptics

  • 30 May 2019: OIA Response: Pharmaceutical budget bid and final budgets

  • 29 May 2019: OIA Response: Insulin needles and syringes data

  • 23 May 2019: OIA Response: Pharmaceutical budget bid

  • 22 May 2019: OIA Response: Pertuzumab renewals data

  • 20 May 2019: OIA Response: Venlafaxine brand change roll out plan

  • 15 May 2019: OIA Response: Lamotrigine correspondence

  • 15 May 2019: OIA Response: Meningococcal W and Scout Jamboree

  • 13 May 2019: OIA Response: Pembrolizumab criteria

  • 9 May 2019: OIA Response: Vaccine costs

  • 30 April 2019: OIA Response: Daivobet gel dispensing data

  • 26 April 2019: OIA Response: PrEP Data

  • 24 April 2019: OIA Response: Parental leave policies

  • 16 April 2019: OIA Response: Antiepileptic medicines data

  • 15 April 2019: OIA Response: Adrenaline autoinjector cost utility analysis

  • 8 April 2019: OIA response: Sleeping medicines data

  • 01 April 2019: OIA Response: Erlotinib and other medicines data

  • 13 March 2019: OIA Response: Summary of factors determining CPB expenditure

  • 27 February 2019: OIA Response: Pembrolizumab and nivolumab data

  • 26 February 2019: OIA Response: Drug shortages

  • 8 February 2019: OIA Response: Waitangi Tribunal research report

  • 29 January 2019: OIA Response: Zytiga data

  • 14 January 2019: OIA response: Technology Assessment Reports for pembrolizumab in advanced melanoma

Back to top

Pharmac - Te Pātaka Whaioranga.

  • Community Schedule
  • Hospital Medicines (HML)
  • Application Tracker
  • Contact us
  • Follow us
  • Facebook
  • LinkedIn
  • Twitter

Shielded site.

  • Copyright
  • Disclaimer
  • Privacy statement
  • Subscribe

New Zealand Government.